The Food and Drug Administration approved Revuforj from Syndax (SNDX) Pharmaceuticals, a menin inhibitor, for relapsed or refractory acute leukemia with a lysine methyltransferase 2A gene translocation in adult and pediatric patients one year and older.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SNDX:
- Biotech Alert: Searches spiking for these stocks today
- Charter to acquire Liberty Broadband, Spotify reports Q3 beat: Morning Buzz
- Syndax price target lowered to $18 from $23 at Scotiabank
- Leerink views Syndax data as potentially positive for Kura Oncology’s ziftomenib
- Elliott confirms big Honeywell stake, Home Deport reports Q3 beat: Morning Buzz